Elegant talk of #interferon #gamma in #pyoderma #gangrenosum Vs #PG + #pyogenic #arthritis +#acne #autoinflammatory #syndromes #Papa syn IL18 differences between PG alone and together in syndrome #JAKi May be helpful #EULAR2024 @eular_org @RheumNow @ARD_BMJ @ACR_Journals https://t.co/plYldVdolS

In the ‘why therapeutic drug monitoring’ debate, we’ve heard a lot about TDM utility, but the con argument is interesting. Desiree van der Heijde compares TDM to IL-6 levels, which never displaced her DAS then puts up some confronting points. Interesting #EULAR2024 @RheumNow https://t.co/7zomungi3e

I have to say: upadacitinib looks very decent for GCA. Not a panacea, but it definitely does something & good safety during trial. Would love to eventually see: - H2H comparative effect vs toci, secukinumab - structural outcomes - long-term safety #EULAR2024 PBA0001 @RheumNow https://t.co/pHZgCKsoA9 https://t.co/5BxCkkLPti

#EULAR2024 POS0152 How prevalent is severe refractory #lupus? Multicentre cohort in Asia defined this as SLEDAI-2K=>10 + on GC + immunosuppressant. One in 7 met this definition, assoc w high activity & low T2T achievement. Useful for sample size calc for clinical study @RheumNow https://t.co/bq4gxX7kjI

#EULAR2024 POS0191 Development and validation of plasma biomarkers to predict #lupus flare in the next 12 weeks. Quick turnover results. Need to focus on steps to bring these novel tools from bench to clinical practice @RheumNow https://t.co/64EppGI7bv

#EULAR2024 OP0008 Phase 2 #Sjogren RCT Iscalimumab, anti-CD40mAb in two cohorts (1=High systemic activity; 2=High symptom burden but low systemic) showed sustained improvement in ESSDAI & ESSPRI at 48wks in ISC-ISC group, as well as those switched at 24wks from PBO-ISC @RheumNow https://t.co/GuifDHA0lK

#EULAR2024 OP0089 Promising data from Phase 2 RCT on dual blockade depletion & BAFF-R-i, Ianalumab in #lupus. After 24 wks double-blind, sustained response (SRI-4 + Pred ≤5mg/d or ≤ BL dose) was seen in IAN-IAN group while PBO-IAN improved in open label phase at 48wks @RheumNow https://t.co/MUo76ii4vB

12-week ARGO Phase 2 trial data of IL-17A- and IL-17F-inhibiting Nanobody sonelokimab delivers rapid onset and robust levels of clinical response, including high-threshold outcomes, compared with placebo in patients with active PsA, with a favorable benefit–risk profile. It met… https://t.co/4wj222FkzP https://t.co/ipUSjKvpuB

When patients say their joints are swollen, what does it mean? Easy to dismiss it as a symptom, but this clinically suspect arthralgia cohort from Leiden shows: - some correlation with MRI/USS findings - predicts RA development still worthwhile! #EULAR2024 POS0609 @RheumNow https://t.co/dw2p5Eo26C

#Editors Picks @eular_org @ARD_BMJ @ACR_Journals Can #rheumatologists effectively #dx of #ankylosing #spondylitis? 👍 552 pts - 1/3 axSpA w high certainty Certainty of #dx changed over time 2 features #sacroileitis good #nSAID response #EULAR2024 @RheumNow https://t.co/NN3GZTmgn9